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Abstract
Background: Human papillomavirus (HPV) testing is included in the cervical cancer screening program in the triage of
women with equivocal (ASC-US) or low-grade (LSIL) cytological lesions. These women have an increased risk for developing
high grade dysplasia and cancer (CIN2+) compared to women with normal cytology. However, in order to avoid
unnecessary follow-up, as well as overtreatment, a high positive predictive value (PPV) of the triage test is important.
Methodology/Principal Findings: The HPV test PreTect HPV-Proofer, detecting E6/E7 mRNA from the HPV types 16, 18, 31,
33 and 45, is used as triage test together with repeat cytology. PPV data for HPV E6/E7 mRNA testing during the period from
January 2006 up to June 2009 are reported. In total, 406 of 2099 women (19.3%) had a positive HPV test result. Of the
women with a positive test result and with a histological diagnosis (n=347), 243 women had histological high-grade
dysplasia or cancer (CIN2+), giving a PPV of 70.0% (95% confidence interval [CI], 65.2%–74.8%). For HPV 16 or HPV 33
positive women above 40 years of age, the PPV was 83.7% (95% CI, 73.3%–94.0%) and 84.6% (95% CI, 65.0%–100.0%)
respectively. The PPV of test positive women with HSIL cytology was 94.2% (95% CI, 88.7%–99.7%).
Conclusions: When the result in triage is HPV mRNA positive, our data suggest direct treatment for women above 40 years
of age or for women with a concurrent cytological HSIL diagnosis, contributing to better clinical safety for these women. In
addition, by decreasing the time to treatment, thereby reducing the number of recalls, the patient management algorithm
will be considerably improved, in turn reducing follow-up costs as well as unnecessary psychological stress among patients.
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Introduction
Cervical cancer can be prevented by early detection and
treatment of precancerous lesions. In Norway, a cervical cancer
screening program was introduced in 1995, recommending all
women between 25 and 69 years of age to have a cytological cell
sample (Pap-smear) every three years. Since the introduction of the
program, the coverage of women taking a Pap-smear has
increased and consequently, the rate of cervical cancer is reduced
[1]. Despite this well organized screening program, about 300
women get cervical cancer in Norway each year (age adjusted
cancer incidence of 8.9 per 100 000 person-years) [2] about half of
whom are following the program [1]. This can be explained by a
generally low clinical sensitivity of cytology and by subjectivity and
poor reproducibility [3]. These limitations are mainly a concern in
primary screening, but are also a concern in secondary screening
where cytology is used to triage women with equivocal or low-
grade cellular changes. However, in secondary screening, women
with cellular changes are already found and will be closely
followed up with the methods available. It is therefore important to
identify women with true precancerous lesions or with cervical
cancer, i.e. women requiring immediate treatment. In addition, it
is important to avoid overtreatment by detecting as few false
positives as possible [4,5]. Considering all of the above, this has
drawn attention to the need for objective and accurate diagnostic
tests providing additional information in order to identify women
having a true risk of developing cancer.
As a result of the finding that human papillomavirus (HPV) is a
necessary cause of cervical cancer, HPV testing has been included in
cervical cancer screening in several countries. In Norway, HPV
testinghasbeenincludedinsecondaryscreeningsince2005(Figure1):
If the cytology is defined as ASC-US (atypical squamous cells of
undetermined significance) or LSIL (low-grade squamous intraepi-
thelial lesions), the woman is referred to a second Pap-smear (repeat
cytology) and an HPV test after six months. If the repeat cytology
reveals ASC-US or LSIL and the HPV test is positive, the woman is
referred to colposcopy. Women with normal repeat cytology but with
a positive HPV result are tested for HPV persistence and if positive,
referred to colposcopy. Women with ASC-H or HSIL are referred to
colposcopy and biopsy independent of the HPV result.
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available. One of these tests is the PreTect HPV-Proofer assay
(NorChip AS, Norway), detecting HPV E6/E7 mRNA from the
five most prevalent types causing cervical cancer. The University
Hospital of North Norway has five years of experience with the use
of this test. The argument for choosing this test in secondary
screening was the need for a clinically specific test to find the
women truly needing follow-up and essentially requiring referral to
treatment. The HPV E6/E7 mRNA test has been shown to have a
higher clinical specificity and positive predictive value (PPV) than
HPV DNA tests [6–12] and thus, in our opinion, qualifies better
than HPV DNA tests for this purpose.
The PPV reflects the proportion of patients with a positive test
result who are correctly diagnosed and gives information about the
accuracy of the test. At our hospital we have repeatedly observed
that women with a cytological normal, ASC-US or LSIL lesion at
triage, and who are HPV mRNA positive, actually have an
underlying high-grade lesion or cancer which is revealed at
colposcopy and biopsy. In addition, re-evaluation of the
cytological or histological slides after a positive HPV test often
reveals more severe cell-changes than first diagnosed. In a previous
paper [13] we report our general results using the HPV mRNA
test in secondary screening (reporting frequency of the different
HPV types, clinical sensitivity, specificity, PPV and negative
predictive value (NPV)). Here, we focus on the PPV of the test,
including more comprehensive data.
Materials and Methods
Ethics Statement
The Regional Committee for Research Ethics has approved the
study. Written consent from the patients for their information to
be stored in the hospital database and used for research was not
needed because the data were obtained and analyzed anony-
mously.
In the routine diagnostic practice at the University Hospital of
North Norway, the HPV E6/E7 mRNA test PreTect HPV-
Proofer (detecting E6/E7 mRNA from the HPV types 16, 18, 31,
33 and 45) is used in the triage of women with an ASC-US or
LSIL diagnosis for the detection of cervical dysplasia and cancer.
The Department of Clinical Pathology receives cervical smears
from the population of Troms and Finnmark County in Northern
Norway. Approximately 23 000 cervical smears are analyzed each
year and from January 2006 to June 2009, smears from 54 326
women aged 25–69 years were analyzed. A total of 2 858 women
(5.3%) were diagnosed with ASC-US or LSIL. For these women,
repeat cytology and the HPV mRNA test were recommended
after six months. Liquid based cytology and HPV mRNA results
were received from 2 099 women (73.4% of the 2 858 women).
The reason for not obtaining HPV mRNA results for all the cases
is the wide use of conventional Pap-smear rather than liquid based
cytology, which does not allow for HPV analysis.
Cells were extracted from the ThinPrepH 2000 (Cytyc
Corporation, Marlborough, MA, USA) for cytological examina-
tion. The HPV mRNA test uses a liquid based sample from the
same material as cytology. The mRNA testing was performed
according to the manufacturer’s instructions (NorChip AS,
Klokkarstua, Norway) and in accordance with national guidelines
for HPV testing (Figure 1).
Cytological and histological diagnoses were obtained from the
diagnostic database (SymPathy) at the Department of Clinical
Pathology, University Hospital of North Norway. Biopsies with
histological high-grade dysplasia or cancer (CIN2+) were evalu-
ated by experienced pathologists. In Norway, the current clinical
threshold for treatment is CIN2+; after histologically confirmed
CIN2+, national guidelines recommend treatment by conization
Figure 1. Flow chart showing the guidelines for HPV E6/E7 mRNA testing. Women with ASC-US or LSIL at triage and with a positive HPV
result are referred to colposcopy and biopsy; if the HPV test is negative, the woman is referred to a third Pap-smear after one year. Women with
normal cytology and a positive HPV mRNA result at triage are recommended to have a third Pap-smear and a new HPV mRNA test after 6 months;
women with a persistent HPV mRNA result are referred to colposcopy and biopsy. Women with ASC-H and HSIL at triage are referred directly to
histological investigation regardless of HPV status.
doi:10.1371/journal.pone.0012724.g001
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to be followed up with a new Pap-smear and HPV test after 6–12
months. Biopsies with uncertain cellular changes are immuno-
stained with p16 in order to detect occult CIN lesions.
Limitations of the study
It is important to note that in clinical practice, the guidelines are
not consistently followed. In contrast to a well planned study,
individual evaluations are frequently made and essentially the
history of the patient is important in the assessment of whether or
not she should be referred to treatment. Different aspects of
deviations are included in the discussion. Furthermore, due to
ethical considerations, conization of every woman is not possible
and therefore the true sensitivity of the test cannot be determined.
Results
Numbers for PPV calculations are presented in Tables 1–3. Of
the 2 099 women who were tested for HPV mRNA, 406 (19.3%)
had a positive test result. Not unexpectedly HPV 16 was the most
dominant type, detected in 205 (50.5%) of the positive women,
followed by HPV 33 (16.0%), HPV 18 (13.8%), HPV 45 (13.5%)
and HPV 31 (6.2%) (Table 2). Of the 406 women with a positive
HPV result, histological data were available for 347 women.
For women being treated (n=230), the diagnosis used for PPV
calculations is the most high-grade histological diagnosis of the
biopsy before treatment or of the cone after treatment; the biopsy
before treatment may have therapeutic effect and therefore the
diagnosis of the biopsy may be the correct one. The diagnosis of
the biopsy is reported for 42 women; for 181 women, the diagnosis
of the cone is reported. Seven women were referred to treatment
directly after abnormal cytology and/or colposcopy and/or a
persistent HPV result and for these women the diagnosis of the
cone is reported.
Of the total women with a positive HPV result and a
histological diagnosis (n=347), 243 women had histological
CIN2+, giving a PPV of 70.0% (Table 1). Of the HPV 16 positive
women, 144 of 179 women with histology had a diagnosis of
CIN2+, giving a PPV of 80.4% (Table 2). Due to the lower rate of
planned children among women .40 years of age, the data for
this age group were analyzed separately (Table 3). For women
planning for children, cervical surgery should, even with a high
PPV of the confirmatory test, always be given higher consider-
ation.
The added value of the HPV mRNA test in detecting women
with high-grade lesions is shown in Table 4 and 5. Table 4
summarizes the number of women with a normal, ASC-US or
LSIL diagnosis at triage found to have an underlying high-grade
lesion after a positive HPV test. Table 5 compares the diagnosis of
the first biopsy with the most high-grade histological diagnosis for
women referred to treatment. HPV mRNA positive women with
benign or low-grade changes at first biopsy are always advised to
be followed with a new Pap-smear and HPV mRNA test after six
months. However this follow-up is commonly inconsistently
performed (for example, only a conventional Pap-smear is taken,
not allowing for HPV testing). Thus, only women referred to
treatment are included in the table.
In total, 13 women were found to have cancer (Table 5), all of
whom were either HPV 16 or 18 positive. Five of these women
Table 1. Triage of women with ASC-US or LSIL.
Cytological
diagnosis at triage
Number of women
with this diagnosis
HPV
positives
Women with CIN2+
among the HPV positives
Number of women with a
histological diagnosis PPV* (95% CI)
Normal 1 191 42 13 20 65.0 (44.1–85.9)
Unsatisfactory 109 16 6 9 66.7 (35.9–97.5)
ASC-US 358 98 45 89 50.6 (40.2–60.9)
AGUS 20 - - -
LSIL 252 115 64 97 66.0 (56.6–75.4)
ASC-H 103 63 50 63 79.4 (69.4–89.4)
HSIL 84 72 65 69 94.2 (88.7–99.7)
Total 2 099 406 243 347 70.0 (65.2–74.8)
*PPV for CIN2+ for HPV mRNA test positives. Only women with a histological diagnosis (biopsy or cone) are included in the calculation.
doi:10.1371/journal.pone.0012724.t001
Table 2. PPV for CIN2+ for the different HPV-types, including all ages.
HPV type
Number of women with
respective HPV type
Women with CIN2+
among the HPV positives
Number of women with a
histological diagnosis PPV* (95% CI)
16 205 144 179 80.4 (74.6–86.3)
18 56 25 50 50.0 (36.1–63.9)
31 25 13 21 61.9 (41.1–82.7)
33 65 37 56 66.1 (53.7–78.5)
45 55 24 41 58.5 (43.5–73.6)
Total 406 243 347 70.0 (65.2–74.8)
*Only women with a histological diagnosis (biopsy or cone) are included in the calculation.
doi:10.1371/journal.pone.0012724.t002
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one had either microinvasive carcinoma or stage 1A carcinoma;
one patient had stage 1B carcinoma. Nine women have undergone
hysterectomy and for four women (aged 26, 29, 32 and 33 years),
conization (possibly with re-conization) was sufficient for elimi-
nating further disease.
Discussion
The main cause of invasive cervical cancer is the deregulated
and persistent production of HPV E6 and E7 oncoproteins [14].
Hence, HPV E6/E7 mRNA is a rational target for detecting HPV
infections leading to cellular transformation. PreTect HPV-
Proofer is a commercial assay for the detection of E6/E7 mRNA
from the five main high-risk HPV types 16, 18, 31, 33, and 45.
Due to the higher clinical specificity and PPV of this method
compared to other HPV tests [6–12], this was the method of
choice at our hospital when HPV testing was introduced in
secondary screening in Norway.
Our data show that when including all age groups, the HPV
mRNA test has a PPV for CIN2+ of 70%. A previous data analysis
[13] shows that the PPV of repeat cytology for CIN2+ is 29.8%
(unpublished data; this number is overrated due to known HPV
status). In a meta-analysis by Marc Arbyn and colleagues [15], a
PPV of repeat cytology of 11.8% for ASC-US and 23.2% for LSIL
is reported; the PPV of repeat cytology at cutoff ASC-US or worse
ranged from 3.8% to 22.2%. Taken together, our results indicate
that the PPV of the HPV mRNA test strongly exceeds that of
repeat cytology, which is an important finding. The 30% with a
positive HPV test but with no confirmatory high-grade lesion may
be explained by the observation that colposcopic biopsy misses 26–
42% of prevalent CIN2+ (depending on the severity of the lesion
and the number of biopsies taken) (Marc Stoler, Eurogin 2010),
with the main problem being the subjectivity in determining the
location of the lesion [16]. The question then arises whether the
30% of the HPV mRNA positive cases with no confirmatory high-
grade histological diagnosis actually may represent false negatives
due to a small lesion or a biopsy not representing the true lesion.
Also, HPV 18 infections have been described as being specifically
difficult to detect histologically and may therefore lead to a false
negative histological diagnosis [17]. Interestingly, in several cases
we have demonstrated that women with an originally benign or
low-grade histological diagnosis have underlying lesions when the
biopsy is more thoroughly examined after a positive HPV mRNA
test result (for example by making deeper sections of the biopsy or
by p16 immunostaining) indicating that, in several cases, a false
negative histological result was revealed.
The PPV of the diagnoses ASC-H and HSIL for CIN2+ are,
according to Norwegian Cancer Registry data, 56.4% and 73.9%
respectively [1]. The respective numbers from our lab are 52.7%
and 76.9% (unpublished data; first cytology 2005–2008, CIN2+
up to end 2008). The data in the present study show that by
including HPV E6/E7 mRNA testing, the PPV of test positive
women with ASC-H or HSIL is 79.4% and 94.2%, respectively.
This strongly suggests that women with HSIL and a positive HPV
mRNA test can be directly referred to treatment. For women with
ASC-H, the HPV test will be a valuable tool in separating women
requiring follow-up (or treatment if .40 years of age or not
planning for children) from women only having a chronic
inflammation (seen in more than 40% of women with ASC-H).
Women with HSIL and a negative HPV mRNA test should be
referred to colposcopy and histology in the traditional way.
Women with ASC-US or LSIL at repeat cytology and with a
positive HPV mRNA test are referred directly to colposcopy and
biopsy. When an HPV test is not used, women with ASC-US and
LSIL are referred to colposcopy and biopsy after three times
repetition of the diagnosis. This means that for women with an
underlying high-grade lesion, the disclosure of their disease will be
delayed with up to two years, which may be critical. The same
applies to women with normal cytology at triage, for whom the
PPV of HPV mRNA test positives for CIN2+ is 65.0%. Women
with normal cytology (when the HPV test is not included) are
referred back to the screening program, emphasizing the
importance of an HPV test for these women. Of note is that the
PPV for mRNA positive women with normal cytology is higher
than the PPV for women with ASC-US (Table 1). This may be
Table 3. PPV for CIN2+ for the different HPV-types, including women .40 years of age.
HPV type
Number of women with
respective HPV type
Women with CIN2+
among the HPV positives
Number of women with a
histological diagnosis PPV* (95% CI)
16 55 41 49 83.7 (73.3–94.0)
18 22 10 19 52.6 (30.2–75.1)
31 8 3 6 50.0 (10.0–90.0)
33 17 11 13 84.6 (65.0–100.0)
45 18 6 14 42.9 (16.9–68.8)
Total 120 71 101 70.3 (61.4–79.2)
*Only women with a histological diagnosis (biopsy or cone) are included in the calculation.
doi:10.1371/journal.pone.0012724.t003
Table 4. Added value of the HPV test; number of HPV mRNA
test positives having an underlying high-grade lesion not
detected at triage cytology.
HPV
type CIN2 CIN3 CxCa
NU N
ASC-
US LSIL N UN
ASC-
US LSIL N UN
ASC-
US LSIL
16 5 07 1 93 21 62 0 0 02 2
18 20 2 3 00 1 4 00 1 0
31 01 1 1 01 1 0 00 0 0
33 10 6 4 11 4 6 00 0 0
45 11 4 3 00 0 2 00 0 0
N = Normal.
UN = Unsatisfactory.
doi:10.1371/journal.pone.0012724.t004
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intervals. It may also be explained by the fact that for women
with normal cytology, the guidelines recommend biopsy only
when a persistent infection is demonstrated (HPV positive with six
months interval) and consequently the risk of having a CIN2+ is
higher.
An HPV mRNA positive HPV 16 result has a PPV for CIN2+
of 80.4% when including all age groups, representing a higher
PPV than the cytological HSIL diagnosis. For the other HPV
types, the PPV is somewhat lower. One explanation for the lower
PPV of HPV 18 and HPV 45 may be the lower degree of
noticeable cell changes related to these infections and the fact that
lesions caused by these HPV-types often are located further up in
the cervical canal (glandular lesions) [17]. Therefore, for these
infections, if the original biopsy is benign or low-grade, diagnostic
conization might be more important than for infections with other
HPV types.
The motivation for looking at the age group .40 years is related
to the lower probability of children planned among women in this
group. Given the impact of cervical treatment (such as LEEP
conization) on pregnancy outcomes [5,18,19], cervical treatment is
more critical for women planning to have children. In addition, if
a high-grade lesion is found in a woman above 40 years of age,
there is a higher chance that the lesion has been present for a
longer period of time, in turn making surgery more important.
Accordingly, for women above 40 years of age, the PPV of 70.3%
(83.7% for HPV16 and 84.6% for HPV 33) suggests that HPV
mRNA test positive women can be referred directly to treatment
without histological confirmation, contributing to a better clinical
safety for this age group. For the 30 women above 40 years of age
with no confirmed high-grade lesion, 14 had a negative HPV test
at follow-up (out of a total of 15 women receiving a follow-up HPV
test; one had a persistent HPV 45 infection). Fifteen women were
followed up by cytology only, and of these, three had ASC-US,
one had LSIL and 11 had at least one normal cytological smear
and were consequently referred back to the screening program.
However, these women may have lesions further up in the cervical
canal that are difficult to detect morphologically, as often seen for
HPV 18 or 45 infections. In our case, nine of these 15 women had
either an 18 or 45 infection. We would therefore suggest that all
women with a positive HPV result should be followed up with a
repeated HPV test after six months. Also, among postmenopausal
women, a higher degree of atrophic changes are present, often
being difficult to distinguish from dysplasia. For these women, an
HPV test will be crucial for the evaluation of the sample and
subsequent follow-up of the woman.
Tables 1 and 2 show that for 59 out of 406 women with a
positive HPV mRNA test, no histological diagnosis is reported.
There may be several reasons for this. First of all, for women with
a normal cytological diagnosis at triage, referral to biopsy is
recommended only if they are found to have a persistent HPV-
infection or a HSIL at follow-up. A new HPV test is only
performed for about half of these women, due to misunderstand-
ings related to the new strategies for clinical management or to the
fact that a conventional Pap-smear is taken, not allowing for HPV
testing. Some times a new cytological smear is done, although a
biopsy has been requested (for example after a persistent HPV
result). If this smear is found to be normal, the woman may
disappear from the system and is a typical example of a woman
‘‘lost in follow-up’’. Another reason for lack of histological data
may be that the woman is pregnant and a biopsy is not
recommended for this group. Alternatively, the woman may have
moved to another city and consequently the follow-up of this
woman has been done elsewhere.
An added value of the HPV mRNA test in detecting women with
high-grade lesions is presented in Table 4, among others showing
that five women with an ASC-US or LSIL diagnosis at triage had
underlying carcinoma revealed after a positive HPV test. Another
added value oftheHPVtest is seen forwomenwith a benignorlow-
grade diagnosis at first biopsy.If the HPV test is positive,a new Pap-
smear and HPV test are recommended after six months. In our
material, 23 women with a benign, uncertain or CIN1 diagnosis at
first histology had an underlying high-grade lesion revealed during
follow-up after a positive HPV result (Table 5). For these women,
the first biopsy or histological slide may not have been represen-
tative for the underlying disease. Alternatively, a microlesion
difficult to detect by colposcopy-directed biopsy or by histology
may have been present. Nevertheless, this in turn emphasizes the
need for additional methods in order to increase the overall
sensitivity of biopsy and histology.
In total, 13 women (with ASC-US, LSIL or HSIL at triage)
were diagnosed with cancer. Interestingly, the HPV test had an
Table 5. HPV mRNA positive women with definite treatment: Diagnosis of first biopsy compared to the most high-grade
histological diagnosis.
Diagnosis of first biopsy Most high-grade histological diagnosis
Benign CIN1 CIN2 CIN3 CxCa Total
No biopsy
1) 1 0 2 407
Benign
2) 0 1 2 609
Uncertain
2) 0 1 0 113
CIN1
2) 0 7 4 902 0
CIN2 0 0 70 33 3 106
CIN3 00 0 7 6 8 8 4
CxCa 0 0 0 011
Total 1 9 78 129 13 230
1)Women referred to treatment directly after a positive HPV result and/or high-grade cytology and/or a previous CIN2+ diagnosis (with or without treatment).
2)HPV positive women with histology ,CIN2 at first biopsy were advised to be followed up with a new Pap-smear and mRNA test after 6 months. Women were referred
to new biopsy and/or treatment on the basis of a persistent HPV infection and/or a HSIL diagnosis at follow-up. Alternatively, the same biopsy may have been re-
evaluated on the basis of a positive HPV result and then revealing a high-grade lesion.
doi:10.1371/journal.pone.0012724.t005
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knowledge that the cytological diagnosis is influenced by the HPV
result and by the follow-up of women with normal or low-grade
cytology due to a positive HPV result (Table 4). Consequently, the
HPV mRNA testing led to an earlier diagnosis and better
prognosis: All but one of these women had a final diagnosis of
either microinvasive carcinoma or stage 1A carcinoma; one
patient had stage 1B carcinoma. Nine women had hysterectomy
and for four women, conization was sufficient to eliminate further
disease.
To conclude, our data suggest a clinical ‘‘test and treat’’
application of the HPV mRNA test: Direct treatment may
contribute to a better clinical safety for test positive women above
40 years of age and for women with a concurrent cytological HSIL
diagnosis. Consequently, by decreasing the time between testing
and treatment, thereby reducing the number of recalls, the patient
management algorithm will be considerably improved and will in
turn reduce follow-up costs and more importantly, unnecessary
psychological stress among patients will be avoided.
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